ZFX and prostate carcinoma: Besides, ZFX has been found to be overexpressed in several solid cancers, including breast cancer [30], prostate cancer [31], acute T-lymphoblastic and myeloid leukemia [32], hepatocellular carcinoma [33], and non-small cell lung carcinoma [34].